Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gempicker, I was also ROFLMAO when I watched this 'hit piece'. Too funny, like you said Dr. Ralph Bright, general practioner turned "self-taught" cosmetic surgeon continues to use Intellicells process with some slight 'tweaks' he made to improve the process. I think this has been talked about in the past but intellicell should be suing this guy for breach of contract. He's treated a total of 400 patients over the last 4 years and at $9K a pop he's raked in $3.6 million australian ( 1.00 AUD = 0.9008 81 USD) which is roughly $3,242,880 US dollars. Not considered chump change by any means. Granted he did pay intellicell $700K for the technology, he has gone on to license HIS methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA), basically the equivalent of the FDA in Australia. How much money has he brought in with licensing fees as well, selling HIS new and improved method where he doesn't leave the probe in as long and keeps the sample cooled?. Give me a break!
Here is something else to get you back on the floor, GEM.
Did you happen to catch that segment of the video where Dr. Victor is being interveiwed and he says, "In one hour and one treatment we can make your dreams come true"? This can be heard starting at 3 minutes and 25 seconds into the 'hit piece'. see link here
Now take a look at this link which can be found on youtube and is actually from some 'cheesy' infomercial that Dr. Victor had done for one of his other companies. "LaserSculpt" Listen to the link at 35 seconds into the video. Quote Dr. Victor, "By taking LaserSculpt in one hour and one treatment we can make your dreams come true. see link here.
This quote was totally cherry picked and used completely out of context to make it seem like Dr. Victor is saying that intellicell will make all of your dreams come true with just one treatment of stem cells. SCANDALOUS! He was talking about LaserSculpt and making someones dream come true to finally get rid of those pesky 'love handles'.
Can you say Shenanigans? Dr. Victor has always been clear that Intellicell does not make clinical claims on the treatments they perform because such claims cannont be backed with clinical trials as of yet using the Intellicell process.
I too get the feeling that this is about to go big and this was more than likely an attempt to shake the tree hard of weak retail holders. Doesn't seem to be doing much good though considering we are sitting unchanged with a share price of .0013 and a total volume of 8.7 million shares.
Shatner2
And let's also not forget the amazing results seen in IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey. The results were published in The American Journal of Medicine. Anyone heard of it? Link to full text publication
Here's a couple of highlights from the paper.
-73 year old white guy with a ton of heart issues including recurrent angina, multiple angioplasties resulting in the placement of 9 coronary stents, previous triple bypass graft using leg vein. Pt. was in the ICU with an EF (ejection fraction) of only 20%. Normal EF for a male of this age is around 65%. Basically, this guys cardiac output is so low that all he could probably do was lie in bed. This guy is super sick and this cellular therapy is a last resort intervention for the patient's dysfunctional heart.
-used intellicells technology to obtain adipose derived stromal vascular fraction cells. 100 million adipose-derived stromal vascular fraction cells were delivered via localized intramyocardial injection (left apex), and 200 million adipose-derived stromal vascular fraction cells were delivered systemically via intravenous injection
-"Within 7 days of the procedure, transesophageal echocardiography was performed to evaluate recovery of the patient's left ventricular function. His ejection fraction improved to 35% with recovery in the contractility of the previously akinetic inferolateral segment. This confirmed the effectiveness of cell delivery in improving regional and global left ventricular systolic function."
This is huge. An ejection fraction improving from 20% to 35% is a 75% increase in function. This type of cardiac regeneration is unheard of and it happened in a weeks time. It was also observed that the inferolateral segment of his heart which was previously 'non-beating', was observed to be beating on the 7 day follow-up as seen with the echocardiogram. Let's be clear, the heart doesn't just spontaneously regenerate itself to this magnitude in this short of a period.
This is taken from the discussion.
-"Adipose-derived stromal vascular fraction cells may have cardiomyogenic potential. Cellular composition of cells administered included endothelial progenitor cells, vascular smooth muscle cells, mesenchymal stem cells, fibroblasts, growth factors, and pericytes. This complex population has shown efficacy in repairing damaged tissue to partial restoration of functional normalcy.2"
Note that there are a lot of different cell types and growth factors involved in this therapy as well as mesenchymal stem cells. This study stated that the cell population taken from liposaspirate had approximately 86% viability. The fact that some of the cells are 'dead' doesn't really matter. What matters is that we are seeing amazing results because of multiple processes taking place where other components are acting to 'turn on' our bodies natural regenerative healing capabilities. In essence, the body is being told to grow new heart cells irregardless of the stem cells composing the therapy that was administered.
This is taken from Intellicell Biosciences website and breaks down what exactly is in our cellular therapy. As you can see the composition below is diverse. The regenerative medicine industry may be young yet and can't verify all anecdotal treatment results seen with clinical statistical significance because there hasn't been any or enough clinical trials to prove these results. This will come with time, as well as our understanding of what is actually happening with this cellular fraction that is resulting in the positive benefits seen in the clinic. One can already see the multitude of clinical trials involving stem cells by simply searching clinicaltrials.gov.
IntelliCell® Vascular Fraction Cells
VFC cellular composition:
Adult autologous stem cells (Mesenchymal)
Endothelial Cells
Fibroblasts
Growth Factors
Pericytes
Pre-adipocytes cells
Smooth muscle cells
Blood Cells from the capillaries supply including:
B&T cells
Erythrocytes
Hematopoietic stem cells Endothelial progenitor cells
Macrophages
Mast Cells
Monocytes
Natural killer (NK) cells
Shatner2
Here is an article that should be of interest. Its from the February 2014 edition of Journal of the American Academy of Orthopaedic Surgeons. It's titled, Application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis. It also happens to be the only publication co-authored by our favorite doctors, drs. James Andrews, Adam Anz, and Joshua Hackel from the Pensacola Center of the Andrews' Research and educational institute. The location where they will be conducting our IND clinical trials for osteoarthritis of the knee. Here's a link along with the abstract.
http://www.ncbi.nlm.nih.gov/pubmed/24486753
J Am Acad Orthop Surg. 2014 Feb;22(2):68-79. doi: 10.5435/JAAOS-22-02-68.
Application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis.
Anz AW, Hackel JG, Nilssen EC, Andrews JR.
Abstract:
Advances in our knowledge of cell signaling and biology have led to the development of products that may guide the healing/regenerative process. Therapies are emerging that involve growth factors, blood-derived products, marrow-derived products, and stem cells. Animal studies suggest that genetic modification of stem cells will be necessary; studies of cartilage and meniscus regeneration indicate that immature cells are effective and that scaffolds are not always necessary. Current preclinical animal and clinical human data and regulatory requirements are important to understand in light of public interest in these products.
This article is simply a review of the compilation of current literature at the time of publication in regards to the application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis. Considering we announced our engaging inVentiv Clinical as CRO for osteoarthritis IND a month and a half later (4/14/14), I would consider this review done by the drs. as a means to become totally up to date with current literature as well as current regulatory requirements. All important things when you're about to embark on an IND and begin treating patients.
I'll be interested to see what the clinical trial design will look like but from what I can gather on reviewing other research articles it seems that 3 to 6 months post treatment with adipose derived stem cells is usually the measured primary/secondary endpoint. So depending on how many individuals are enrolled in this trial we could see results pretty quickly after initiation. Once they have gotten the results from a large enough sample size they would want to show that they are statistically significant results seen in terms of growth of cartilage visualized with an MRI and improvements seen using various pain/disability scales. It seems they may have the intention that once they get phase I/II data they will want to publish this data in a research journal.
From the same press release regarding engaging inVentiv as our CRO, Dr. Victor says, "This IND study is important for proving the company's patented technology of Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate." Think about this for a second. We're not just only conducting an IND for osteoarthritis of the knee. We're looking to prove with statistical significance that our technology not only works but works better. Once they show that cartilage is grown and pain/disability is improved with statistical significance and they have that published in a peer reviewed journal we will be golden. After all, a joint is a joint. Drs. could use this "off-label". Using the reasoning that if it grew cartilage and improved pain/disability scores in the knee osteoarthritis, then why wouldn't it work in cases involving the elbow, ankle, rotator cuff, meniscus, cartilage deficiencies, etc?
Not only will our new national sales director be able to point at some hard peer reviewed evidence when selling drs. on the idea of adding an intellicell lab in their facitlity but the doctors will also be able to show this evidence to their patients. Remember, because our process doesn't use exogenous enzymes such as collagenase to separate the SVF and we don't culture our cells (competitors culture cells using Bovine serum) we aren't obligated by the FDA to perform an IND in order to treat patients using our technology. All we need is the initial proof and we'll have that added to our arsenal to help ramp up revenues at our current and future lab locations. Anywho, those are my thoughts.
Shatner2
Nice 5,078,000 hit on the ask at .0013. Now 880k bid .0013. Ask ~960k at .0014. Over 16 million sitting on the bid at .0011. Total daily volume 15.3 million shares.
Over 6000 patients treated in Cuba with stem cells in the first half of 2014
http://www.cadenagramonte.cu/english/index.php/show/articles/19571:more-benefitted-in-cuba-with-stem-cell-therapy
Check out the exponential growth we are seeing in the amount of patients being treated with stem cells in Cuba. A news article from February of this year stated that there had been roughly 5000 patients treated with stem cell therapy in Cuba since the procedure first started being used there over a decade ago. Now just in the first half of 2014 we are seeing 6,195 patients treated in Cuba with stem cell therapy. Treatment using stem cells has now expanded to 14 provinces since first being administered in 2004. And its no wonder, in patients with arterial conditions (lower limb ischemia) in the lower limbs, treatment resulted in amputations being avoided in 58-80 percent of patients. These are not small numbers we are talking about here. These results are significant. Intellicell in the past has talked about pursuing lower limb ischemia IND using their patented adipose derived stromal vascular fraction therapy I would think this is warranted given the excellent results we are seeing out of Cuba.
Shatner
More Benefitted in Cuba with Stem Cell Therapy
Havana, Cuba, Sep 8.- A total of 6 thousand 195 patients were treated in Cuba with stem cells in the first half of 2014, while the medical procedure has been expanded to 14 provinces since it was first administered here in 2004.
Doctor Porfirio Hernandez, vice-director of the Hematology and Immunology Institute, told Granma newspaper that the cellular treatment is promising particularly for patients with serious artery condition in lower limbs since it avoids amputation between 58 and 80 percent of them.
Promising results have been reported in other conditions, such as bone fractures, degenerative knee malfunctions, spinal cord problems, neurological conditions linked to strokes, among many others, the doctor said.
Cellular therapy is considered one of the major medical advancements over the past years bearing in mind its favorable prospects for people suffering from chronic diseases, who do not respond to conventional treatment.(acn).
Testis, Testis! 1, 2, 3?
Scientists identify rare stem cells in testis that hold potential for infertility treatments
http://www.healthcanal.com/male-reproductive/54825-scientists-identify-rare-stem-cells-in-testis-that-hold-potential-for-infertility-treatments.html
DALLAS – Rare stem cells in testis that produce a biomarker protein called PAX7 help give rise to new sperm cells — and may hold a key to restoring fertility, research by scientists at UT Southwestern Medical Center suggests.
Researchers studying infertility in mouse models found that, unlike similar types of cells that develop into sperm, the stem cells that express PAX7 can survive treatment with toxic drugs and radiation. If the findings hold true in people, they eventually could lead to new strategies to restore or protect fertility in men undergoing cancer treatment.
“Unfortunately, many cancer treatments negatively impact fertility, and men who receive such treatments are at high risk of losing their fertility. This is of great concern among cancer patients,” said Dr. Diego H. Castrillon, Associate Professor of Pathology and Director of Investigative Pathology. “The PAX7 stem cells we identified proved highly resistant to cancer treatments, suggesting that they may be the cells responsible for the recovery of fertility following such treatments.”
Infertility, which the Centers for Disease Control estimates affects as many as 4.7 million men in the United States, is a key complication of cancer treatments, such as chemotherapy and radiation therapy.
The new findings, presented in the Journal of Clinical Investigation, provide valuable insight into the process of sperm development. Known as spermatogenesis, sperm development is driven by a population of “immature” stem cells called progenitors in the testes. These cells gradually “mature” into fully differentiated sperm cells. Dr. Castrillon and his team tracked progenitor cells that express the protein PAX7 in mouse testes, and found that these cells gradually give rise to mature sperm.
“We have long known that male fertility is driven by rare stem cells within the testes, but the precise identity of these stem cells has been disputed,” said Dr. Castrillon, who holds the John H. Childers, M.D. Professorship in Pathology. “Our findings suggest that these rare PAX7 cells are the key cells within the testes that are ultimately responsible for male fertility.”
Importantly, even after exposure to toxic chemotherapy or radiation treatments, the PAX7-expressing cells continued to divide and thus could contribute to restoring sperm development.
http://charlotte.twcnews.com/content/news/711330/stem-cell-research-for-als-causes-concern-in-catholic-community/
“So there are alternative ways that the stem cell research can move forward not involving fetal research. I think if people want to contribute to ALS research, one can demarcate where it should go,” said Dr. Brooks.
How about funding stem cell research that utilizes Intellicell's technology to harvest SVFCs (stromal vascular fraction cells) from adipose. In the announcement of the addition of Raymond Hill to Intellicell's BOD. "IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a significant addition to the Board of Directors as Mr. Hill brings substantial experience in the field of FDA clinical trials. Mr. Hill is a valuable asset to the company, especially as IntelliCell is embarking on FDA IND clinical claim studies for Osteoarthritis with Dr. James Andrews as well as exploring clinical studies for Autism and ALS."
Stem Cell Research for ALS Causes Concern in Catholic Community
By: Leslie Mayes 08/31/2014 02:22 PM ShareThis Facebook Tweet Email Text size: + -
TWC News: Stem Cell Research for ALS Causes Concern in Catholic Community
Play now
CHARLOTTE—The ALS ice bucket is almost impossible to avoid online; but the challenge, specifically the type of research that it's proceeds may be funding, have some in the Catholic church giving pause.
“There is some concern among a lot of Catholics that the ALS foundation has done a little bit of embryonic stem cell research. And even a little bit can be too much” said David Hains, the Communications Director for the Charlotte Diocese.
Hains said the Diocese, along with others around the country, oppose the use of embryonic stem cells for any sort of medical research. Its research the ALS Association, prime beneficiary of the challenge, has reportedly used in the past.
“In order to do embryonic stem cell research, you have to destroy an embryo. An embryo is life it is a human being even though it has an almost countable number of cells” said Hains.
Since the challenge went viral, raising upwards of $100 million for the ALS Association this summer, Catholic organizations around the country have been grappling with how to couple support for a cure with the reality of their faith.
Charlotte ALS research leader Dr. Benjamin Brooks said it can be done.
“So there are alternative ways that the stem cell research can move forward not involving fetal research. I think if people want to contribute to ALS research, one can demarcate where it should go,” said Dr. Brooks.
Hains said the Diocese still wants Catholics to donate to ALS, but support organization’s whose scientific practices are fully in line with their personal religious values.
- See more at: http://charlotte.twcnews.com/content/news/711330/stem-cell-research-for-als-causes-concern-in-catholic-community/#sthash.DQ3h3SKY.dpuf
Shatner
Did a google search of
"Issuer Direct at 919-481-4000 ext. 111"
Found multiple websites with the exact same statement, "This service has expired. Please contact Issuer Direct at 919-481-4000 ext. 111 to renew service."
MetPro
centorenergy
CannabisScience
LibertySilver
viggle
More than likely some server error related to the service that Issuer Direct provides to its clients or its time to pay the bill to renew the service.
Shatner
Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS
http://www.ncbi.nlm.nih.gov/pubmed/25113670
Stem Cells. 2014 Aug 11. doi: 10.1002/stem.1812. [Epub ahead of print]
Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS.
Forostyak S1, Homola A, Turnovcova K, Svitil P, Jendelova P, Sykova E.
Author information
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder resulting in a lethal outcome. We studied changes in ventral horn perineuronal nets (PNN) of superoxide dismutase 1 (SOD1) rats during the normal disease course and after the intrathecal application (5×105 cells) of human bone marrow mesenchymal stromal cells (MSCs) post symptom manifestation. We found that MSCs ameliorated disease progression, significantly improved motor activity and prolonged survival. For the first time, we report that SOD1 rats have an abnormal disorganized PNN structure around the spinal motoneurons and give different expression profiles of chondroitin sulfate proteoglycans (CSPGs), such as versican, aggrecan and phosphacan, but not link protein-1. Additionally, SOD1 rats had different profiles for CSPG gene expression (Versican, Hapln1, Neurocan and Tenascin-R), whereas Aggrecan and Brevican profiles remained unchanged. The application of MSCs preserved PNN structure, accompanied by better survival of motorneurons. We measured the concentration of cytokines (IL-1a, MCP-1, TNF-a, GM-CSF, IL-4 and IFN-?) in the rats' cerebrospinal fluid and found significantly higher concentrations of IL-1a and MCP-1. Our results show that PNN and cytokine homeostasis are altered in the SOD1 rat model of ALS. These changes could potentially serve as biological markers for the diagnosis, assessment of treatment efficacy and prognosis of ALS. We also show that the administration of human MSCs is a safe procedure that delays the loss of motor function and increases the overall survival of symptomatic ALS animals, by remodelling the recipients' pattern of gene expression and having neuroprotective and immunomodulatory effects. Stem Cells 2014.
Here is another abstract, this one from the recent August 2014 issue of Stem Cells detailing once again the amazing positive effects seen when administering MSCs in a disease model for ALS. This particular study utilized MSCs harvested from human bone marrow. Keep in mind only 500K MSCs were delivered intrathecally into each animal tested. This process would require harvesting MSC's from bone marrow aspirate from which one could only obtain a yield of roughly 10K cells per harvest. These cells would then require expansion (not legal in US) in order to obtain the 500K cells needed for therapy. In comparison, Intellicells ultrasonic cavitation would require no tissue expansion and can yield anywhere between 500 million to 1.3 billion adipose derived mesenchymal stem cells from one harvest of roughly 60cc of adipose lipoaspirate. This technique gives the opportunity to treat each patient with a greater number of MSCs, in turn possibly resulting in even better clinical outcomes. IMO
Shatner
Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis.
http://www.ncbi.nlm.nih.gov/pubmed/24794182
Cytotherapy. 2014 Aug;16(8):1059-72. doi: 10.1016/j.jcyt.2014.02.003. Epub 2014 May 1.
Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis.
Boido M1, Piras A2, Valsecchi V2, Spigolon G2, Mareschi K3, Ferrero I3, Vizzini A2, Temi S2, Mazzini L4, Fagioli F3, Vercelli A2.
Author information
Abstract
BACKGROUND AIMS:
Mesenchymal stromal cells (MSCs), after intraparenchymal, intrathecal and endovenous administration, have been previously tested for cell therapy in amyotrophic lateral sclerosis in the SOD1 (superoxide dismutase 1) mouse. However, every administration route has specific pros and cons.
METHODS:
We administrated human MSCs (hMSCs) in the cisterna lumbaris, which is easily accessible and could be used in outpatient surgery, in the SOD1 G93A mouse, at the earliest onset of symptoms. Control animals received saline injections. Motor behavior was checked starting from 2 months of age until the mice were killed. Animals were killed 2 weeks after transplantation; lumbar motoneurons were stereologically counted, astrocytes and microglia were analyzed and quantified after immunohistochemistry and cytokine expression was assayed by means of real-time polymerase chain reaction.
RESULTS:
We provide evidence that this route of administration can exert strongly positive effects. Motoneuron death and motor decay were delayed, astrogliosis was reduced and microglial activation was modulated. In addition, hMSC transplantation prevented the downregulation of the anti-inflammatory interleukin-10, as well as that of vascular endothelial growth factor observed in saline-treated transgenic mice compared with wild type, and resulted in a dramatic increase in the expression of the anti-inflammatory interleukin-13.
CONCLUSIONS:
Our results suggest that hMSCs, when intracisternally administered, can exert their paracrine potential, influencing the inflammatory response of the host.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Publication found in the August 2014 issue of Cytotherapy. Human mesenchymal stromal cell transplantation therapy seen to exert strongly positive effects as seen in disease model for ALS. Dr. Victor has stated recently that Intellicell Biosciences plans to pursue an IND for use of SVFCs in treating ALS. By reviewing the recent literature, regarding MSCs in the treatment of ALS disease model, using a pub med search you can see the great potential that these stem cells hold as a potential treatment for ALS.
Shatner
http://www.ncbi.nlm.nih.gov/pubmed/23375182
Arthroscopy. 2013 Apr;29(4):748-55. doi: 10.1016/j.arthro.2012.11.017. Epub 2013 Jan 29.
Mesenchymal stem cell injections improve symptoms of knee osteoarthritis.
Koh YG1, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ.
Author information
Abstract
PURPOSE:
The purpose of this study was to evaluate the clinical and imaging results of patients who received intra-articular injections of autologous mesenchymal stem cells for the treatment of knee osteoarthritis.
METHODS:
The study group comprised 18 patients (6 men and 12 women), among whom the mean age was 54.6 years (range, 41 to 69 years). In each patient the adipose synovium was harvested from the inner side of the infrapatellar fat pad by skin incision extension at the arthroscopic lateral portal site after the patient underwent arthroscopic debridement. After stem cells were isolated, a mean of 1.18 × 10(6) stem cells (range, 0.3 × 10(6) to 2.7 × 10(6) stem cells) were prepared with approximately 3.0 mL of platelet-rich plasma (with a mean of 1.28 × 10(6) platelets per microliter) and injected into the selected knees of patients. Clinical outcome was evaluated with the Western Ontario and McMaster Universities Osteoarthritis Index, the Lysholm score, and the visual analog scale (VAS) for grading knee pain. We also compared magnetic resonance imaging (MRI) data collected both preoperatively and at the final follow-up.
RESULTS:
Western Ontario and McMaster Universities Osteoarthritis Index scores decreased significantly (P < .001) from 49.9 points preoperatively to 30.3 points at the final follow-up (mean follow-up, 24.3 months; range, 24 to 26 months). Lysholm scores also improved significantly (P < .001) by the last follow-up visit, increasing from a mean preoperative value of 40.1 points to 73.4 points by the end of the study. Likewise, changes in VAS scores throughout the follow-up period were also significant (P = .005); the mean VAS score decreased from 4.8 preoperatively to 2.0 at the last follow-up visit. Radiography showed that, at the final follow-up point, the whole-organ MRI score had significantly improved from 60.0 points to 48.3 points (P < .001). Particularly notable was the change in cartilage whole-organ MRI score, which improved from 28.3 points to 21.7 points (P < .001). Further analysis showed that improvements in clinical and MRI results were positively related to the number of stem cells injected.
CONCLUSIONS:
The results of our study are encouraging and show that intra-articular injection of infrapatellar fat pad-derived mesenchymal stem cells is effective for reducing pain and improving knee function in patients being treated for knee osteoarthritis.
LEVEL OF EVIDENCE:
Level IV, therapeutic case series.
Copyright © 2013 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.
Looking forward to FDA response on pre IND filing for Osteoarthritis. Should hear response very soon. Interested to see the specifics of the IND. Will patients also be treated using the arthroscope to remove debridement to affected knee prior to treatment with SVFC's? Always great when you get such statistically significant p-values (P<.001) in the clinical outcomes as measured by the Western Ontario and McMaster Universities Osteoarthritis Index, the Lysholm score, and the visual analog scale (VAS) for grading knee pain. As well as the comparison of magnetic resonance imaging (MRI) data collected both preoperatively and at the final follow-up.
Its nice to see that the improvements in both clinical and MRI results were positively related to the number of stem cells injected. This study saw these statistically significant results with an mean of only 1.18 million stem cells injected intraarticularly per patient. Intellicell's method of ultrasonic cavitation can yield anywhere between 500 million to 1.2 billion Mesenchymal Stem Cells per 60 cc harvest of adipose lipoaspirate. Typical treatments by intellicell use 200 million MSCs depending on condition. 100 million administered via IV therapy, and the other 100 million administered locally (example intraarticularly, into the knee joint for OA, osteoarthritis). The remaining cells from the 60 cc adipose harvest can be cryopreserved (Intellicell's other business arm, Cryopreservation) and used at a later date for additional treatments. The question is, what type of improvements are we going to see in our OA IND with Dr. Andrews using Intellicell's high cell count Rx? Since the results are positively related to number of stem cells, I'd venture to say we can expect drastic improvements. We're talking at least an 100 fold increase in the amount of cells delivered compared to this clinical trial. IMO.
Shatner
Excerpt from InVentiv Health website
Ray Hill, Executive Vice President, inVentiv Health
Ray Hill brings extensive experience in successfully growing pharmaceutical services businesses and leading productive teams to the organization. He has lived and worked in Asia, Europe, and the United States.
Prior to joining inVentiv Health in 2012, Mr. Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he led an aggressive strategy of organic growth and acquisitions – building the business to $500M in 2010, and then helping to take the company private[/b]. Prior to IMS, Mr. Hill held a series of other positions in pharmaceutical consulting. He earned a bachelor’s degree from Cornell University and a master’s degree from Duke University.
Yes, Mr. Ray Hill is an excellent addition to Intellicell's BOD. You can see that he has a history of building businesses and then helping to take them private. Anyone care to speculate on the possibility of him helping to ramp up Intellicell's business model and then taking it private/buy out?
Shatner
Did you say GUMS? BOOOOMMMM!!
NEW YORK, NY--(Marketwire -10/20/11)- IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK - News) (Pinksheets: SVFC.PK - News) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today a study published regarding the efficacy of IntelliCell's proprietary SVF in the treatment of gum recession.
The pilot study, published in the October 2011 edition of The Journal of Implant & Advanced Clinical Dentistry, is authored by Nicholas Toscano, DDS, MS, Danny Holtzclaw, DDS, MS, and Steven Victor, MD.
The pilot study, which was a single center study that included 7 female and one male patient ranging from 23 to 45 years of age with gingival recession, showed that Mucograft® collagen matrix combined with SVF treatments may be a viable and advantageous alternative to treating gum recession and potentially eliminate the need for invasive harvesting of gum tissue. By the end of the six-month prospective study, the mean increase in root coverage was 87% for the patients treated. Sixty-six percent of treated patients achieved 100% root coverage. These numbers indicate that gum recession was reversed, with gum tissue growing back over the root area. This was achieved without having to transplant tissue from another part of the mouth into the gum line. Post-treatment, patients reported little or no pain and swelling.
"This is a very encouraging study. Gingival recession is a significant issue in dentistry and IntelliCell is offering a new, potentially superior, non-invasive solution that minimizes patient discomfort and improves outcomes. Dentistry is one of numerous fields in which our SVF may show efficacy," stated IntelliCell Chairman and CEO, Dr. Steven Victor. "This clearly exhibits the potential functionality of the cells contained in the SVF we manufacture using our proprietary process. We intend to seek out opportunities to conduct clinical research and publish in peer reviewed journals in order to quantify the efficacy results of SVF across multiple medical disciplines."
"I am really excited about stromal vascular fracture stem cells and the impact on regenerative dentistry. Future research could prove this to be a major breakthrough in oral and maxillofacial reconstruction," stated Dr. Nicholas Toscano, the periodontist who ran the study.
According to information posted on a website maintained by Photopharmica, the market for the treatment of periodontal disease reached $6 billion in 2000. The information further states that, "Periodontal disease is the most prevalent disease in humans -- more prevalent than heart disease. Degenerative periodontal disease affects 20+% of the population over age 50."
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
Check out the article printed in the October 2011 edition of The Journal of Implant & Advanced Clinical Dentistry. The pictures of the before and after of the gum recession/regeneration are not for the faint of heart, but the improvements are drastic. Please see link below. The article regarding SVFC can be found on pages 23-33. Page 31 has some good pictures of before and after treatment. Remember, don't open this link if you're eating or have a heart condition or something like that.
http://www.nxtbook.com/nxtbooks/specops/jiacd_201110/#/32
Shatner
And lets also not forget about this press release 5 days prior to our announced research collaboration with Dr. Trujillo.
http://www.marketwired.com/press-release/intellicell-biosciences-announces-that-it-is-collaborating-with-global-alliance-innovation-otcqb-svfc-1890343.htm
IntelliCell Biosciences Announces That It Is Collaborating With the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) for Autism, Dementia and Brain Trauma
NEW YORK, NY--(Marketwired - Mar 19, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a collaboration with the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) to use its unique approach to the harvest and use of autologous adipose derived mesenchymal stem cells for clinical neuroscience applications including autism, dementia and brain trauma.
GAIN, a translational neuroscience research organization, designs and develops innovative neuroimaging technologies and computer analyses to assess and treat a variety of neuropsychiatric disorders. GAIN has extensive experience in the imaging and treatment of autism, dementia, brain trauma and other neurological disorders.
IntelliCell BioSciences and GAIN are developing joint protocols with initial efforts focusing on the assessment and treatment of children and adults with Autism, Alzheimer's Dementia, and returning warfighters with blast induced traumatic brain injury. Dr. Sandlin Lowe of the Amen Clinic will lead the studies and treatment of Autism and Alzheimer's disease using Intellicell's patented ultrasonic technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a tremendously moving moment for IntelliCell to work with Dr. Lowe and GAIN on viable treatments for Autism, a disease that continues to grow in our society with unmet clinical needs. We believe that the Intellicell's Stromal Vascular Fraction Cells will offer adults and children with autism a significant improvement in their quality of life. IntelliCell's cellular therapy has also been used to successfully enhance the life of a veteran who had sustained a traumatic brain injury while on duty in Iraq. We believe that the stromal vascular fraction cells have the potential to revolutionize the treatment of Alzheimer's disease as well. We at IntelliCell are excited to have this opportunity to work with the distinguished neuroscientist, Dr Lowe."
According to Sandlin Lowe, MD, Co-Founder and Director of GAIN and Consulting Clinician to the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments is revolutionary. The IntelliCell BioSciences / GAIN collaboration will expand the use of autologous mesenchymal stem cells derived by sonification of the stromal vascular fraction of adipose tissue for many neuropsychiatric conditions including autism, dementia and brain injury.
"We at GAIN look forward to an exciting and fruitful collaboration with IntelliCell BioSciences as together we pioneer new methods in translational neuroscience for the imaging and treatment of autism, Alzheimer's dementia, and brain blast injuries," says Dr. Lowe.
Both Drs, Trujillo and Lowe are affiliated with the Amen Clinic. Dr. Trujillo being a medical director and Dr. Lowe being an consulting Clinician to the Amen Clinics New York. Here again, we can see how close we must be to filing another pre IND with the FDA, this time for Autism. This collaboration was initiated around the same time as Dr. Trujillo's nearly 5 months ago. I think its about time we see some fruits of their labors over these last 5 months. In Steps, Raymond Hill!
If you have the time, check out this video documenting a child's life with autism who subsequently received stem cell treatments in Panama at the STEMCELL INSTITUTE. You can see the transformation first hand of the effects of stem cells in the treatment of autism. Amazing!!!!
Ken's Journey To Recovery--Stem Cell Autism Miracle
Shatner
I Remember when this PR came out about 5 months ago. I especially liked this information from the PR back then and now.
Dr. Trujillo's sister, who is afflicted with ALS has been treated as an individual patient with, among other therapies, SVFCs, and showed improvement. The next step is controlled clinical trials.
According to Dr. Trujillo, Chief Psychiatrist at the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments using SVFCs is going to change the world for ALS patients. I am excited to be part of this moment in scientific history and start investigational clinical studies. I believe there is hope for my ALS patients that never existed before."
Obviously, they can't make claims based off of anecdotal evidence and the next step will be controlled clinical trials. However, the fact that Dr. Trujillo's sister has ALS and was treated with SVFC's (among other probably standard therapies) and showed improvement. How much improvement is what I'd like to know. Especially after Dr. Trujillo essentially states that Intellicells SVFC treatments are going to CHANGE THE WORLD for ALS patients and give hope to his ALS patients where none existed before.
I'm thinking he witnessed some pretty dramatic improvements in his sister's condition following treatement with Intellicell's SVFCs for him to be throwing around words like that.
From today's PR on the addition of Raymond Hill to the BOD's
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a significant addition to the Board of Directors as Mr. Hill brings substantial experience in the field of FDA clinical trials. Mr. Hill is a valuable asset to the company, especially as IntelliCell is embarking on FDA IND clinical claim studies for Osteoarthritis with Dr. James Andrews as well as exploring clinical studies for Autism and ALS."
Since the announcement of, entering into a research collaboration to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease), nearly 5 months has passed. It seems logical to think we could possibly be filing a pre IND with the FDA for SVFCs treating ALS at anytime considering its been 5 months in the making. Hence the need for the expertise of our newest member of the BOD Raymond Hill who specializes in handling FDA clinical trials.
I think Dr. Victor needs to take the "ice bucket challenge" to raise awareness for ALS and its potential treatment using stem cells.
Shatner
inVentiv Health Strengthens Clinical Leadership Team
Burlington, Mass. – December 10, 2012 - inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced organizational changes within its clinical group. Raymond Hill is joining the Company as Executive Vice President of Clinical, effective December 12, 2012, and will be responsible for leading the Company’s Clinical business segment, which includes Early Stage, Phase II-IV and Strategic Resourcing.
“We are very pleased to welcome a seasoned industry veteran like Ray to inVentiv and expect that his significant experience in both successfully growing pharmaceutical services businesses and leading productive teams will be an asset to our organization,” said Paul Meister, Chief Executive Officer at inVentiv.
Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private. Before that, he was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business from $100M in 2004 to $500M in 2010. Prior to IMS, Hill held a series of other positions in pharmaceutical consulting. He earned a Bachelor’s Degree from Cornell University and a Master’s Degree from Duke University.
link
NEWS!!! Finally we get our CFO!!!
Also, Director of National Sales.
IntelliCell BioSciences Added New Members to Management Team
Last update: 19/08/2014 9:27:25 am
IntelliCell BioSciences Added New Members to Management Team
NEW YORK, NY--(Marketwired - Aug 19, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Vincent S. Dugan as Director of National Sales and Mr. John Huber III as interim Chief Financial Officer. The focus being to strengthen the launch of the establishment of additional cellular labs, all being cGTP, FDA registered labs, in hospitals and ambulatory surgical centers across the country. IntelliCell will be responsible for training staff on site and will maintain Quality Assurance of all labs from our headquarters in New York.
Mr. Vincent S. Dugan has worked for the past 11 years in the sales of Orthopedic Medical Devices. Vincent has successfully been involved in the launch of over 20 new orthopedic devices from companies such as Johnson & Johnson, Pivot Medical, Checkpoint Surgical, and ConforMis. Besides providing year after year of consistent growth, Vincent had been involved in the recruiting, training, and hiring of countless sales professionals. Through years of relationships, Vincent has developed a national network of healthcare distributors that he will recruit to help IntelliCell place its technology at Ambulatory Surgery Centers and Hospitals throughout the United States.
Mr. John Huber III is a managing partner at Mango & Huber CPAs in Westfield, New Jersey and has been a practicing CPA in the New York/New Jersey metropolitan area for the last 30 years. His firm has provided outsourced CFO services for several SEC companies over the last 10 years. His firm's experience with financial reporting and accounting controls will enable IntelliCell BioSciences, Inc. to manage the increased activity stemming from the placement of additional labs using the patented technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a key point for IntelliCell BioSciences as it launches the establishment of its FDA registered inspected cGTP cellular lab that utilizes its patented technology. The target is orthopedics and pain physicians. With Vincent's experience in this area for over a decade, IntelliCell is excited and believes that it will be successful in establishing its Cellular Lab in Ambulatory Surgery Centers and Hospitals. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with orthopedics and pain a new and improved approach to gaining significant improvements in their qualities of life. John Huber brings his expertise in the financial area to help manage the finances of IntelliCell."
According to Vincent Dugan, "There is a great demand amongst healthcare professionals and patients to provide better outcomes through the use of biologics. The IntelliCell technology is the latest generation of stem cell technology and works to provide improved patient outcomes and satisfaction. We look forward to making this technology available to Ambulatory Surgery Centers and Hospitals across the United States."
John Huber said, "Our firm is looking forward to the challenge of providing top quality CFO services to a medical tech company that has real growth potential and a niche that could very well set a new precedent in health care. The company is at a critical point in its development and will need to strengthen its financial reporting systems."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
(MORE TO FOLLOW) Dow Jones Newswires
August 19, 2014 12:27 ET (16:27 GMT)
Most definitely my friend! I would have highlighted in GREEN if there was the option. I believe the bottom is in. Once people comprehend what is going on here the stock will go higher. Cheers!
IntelliCell BioSciences Complies With Court Order for Ironridge Settlement
Last update: 18/08/2014 11:56:29 am
IntelliCell BioSciences Complies With Court Order for Ironridge Settlement
NEW YORK, NY--(Marketwired - Aug 18, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced that it received a motion from the Supreme Court of the State of New York County of New York dated May 1, 2014 granting its Motion and denying Ironridge's Cross-Motion and directed Intellicell to settle the Order. The Judge "ORDERED, that Ironridge's first-priority security interest under the Security Agreement dated as of May 31, 2012 shall continue until the earlier of (i) payment by Intellicell to Ironridge in immediately available funds of $91,912,42 or (ii) the receipt by Ironridge of the correct Stock Certificate having the tradable value of $91,912.42 in accordance with Section 12.4 of the Committed Equity Agreement." Pursuant to Judge Oing's Order, entered on June 27, 2014 Intellicell delivered to Ironridge's counsel, Richard Haddad, Esq. 53,568,400 common shares of Intellicell having a value of $91,912.42. And pursuant to the Order, Ironridge's security interest in Intellicell's assets has now been extinguished.
See Court Link:
https://iapps.courts.state.ny.us/fbem/DocumentDisplayServlet?documentId=wrPXv/UM6wuA0XWXOmSgpw==&system=prod
The issue with Ironridge was made public by Intellicell in its SEC filings and public relations announcements, IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "the Ironridge case was settled in July, 2014 and there was no Final Enforcement but it was an Order that was complied with in July 2014. I believe this is just another ploy by Ironridge to hurt IntelliCell. We are exploring our legal options."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
(MORE TO FOLLOW) Dow Jones Newswires
August 18, 2014 14:56 ET (18:56 GMT)
UA Heart Surgeon Dr. Zain Khalpey Receives Grant to Understand Healing Power of Stem Cells
Dr. Zain Khalpey Receives Grant to Understand Healing Power of Stem Cells
Here's some recent news that slipped passed my radar. If you remember, Dr. Zain Khalpey is the heart surgeon who was the principle investigator of the recent case study which was published in the American Journal of Medicine at the beginning of this year.
First in Man: Adipose-derived Stromal Vascular Fraction Cells May Promote Restorative Cardiac Function
-"As a last resort intervention for the patient's dysfunctional heart, 100 million adipose-derived stromal vascular fraction cells were delivered via localized intramyocardial injection (left apex), and 200 million adipose-derived stromal vascular fraction cells were delivered systemically via intravenous injection."
-"He had significant left ventricular systolic dysfunction (ejection fraction, 20%) with a thinned, akinetic inferolateral segment."
-"Within 7 days of the procedure, transesophageal echocardiography was performed to evaluate recovery of the patient's left ventricular function. His ejection fraction improved to 35% with recovery in the contractility of the previously akinetic inferolateral segment."
This research conducted by Dr. Zain Khalpey on this 73 year old patient using intellicell's technology to harvest stromal vascular fraction cells for treatment is simply astounding. Keep in mind that a normal range for ejection fraction of a healthy individual is 55-70% and typically is 58%. This patient had an EF of 20% prior to treatment with intellicells SVFC's and 7 days post treatment had an EF of 35%. This represents an improvement of 75%. Also, the patient had recovery in contractility of an area of the heart that was without movement prior to the SVFC treatment.
It appears Dr. Khalpey's newest research for which he has received a grant will be conducted to support his research toward understanding the mechanisms of how stem cell therapy works and how to maximize its potential for repairing damaged hearts.
-“We expect this research will provide important information on the potential of stem cells as mitochondrial donors with better mechanistic understanding of how mitochondria work. We hope that our clinical trials with stem cells in patients with heart failure and with mechanical heart-assist devices will surpass results seen in the field thus far.”
I think we can expect to see more news in the near future from all the great reasearch that Dr. Khalpey has been conducting on stem cells.
Man, MM's WORL and PUMA working overtime on AMB$ this am to try and hold the reins. Keep in mind that CDEL has an order to buy 1 million plus shares at .146. That's $150K+ order. Stock currently trading at .15 with 2.2 million in volume in the first 1 hour 20 minutes of trading. Shaping up to be another nice day.
"Lympro is a Billion dollar a year revenue potential product. BDX is going to help AMBS get Lympro to market soon." -Fouraces
Thanks Fouraces! I'm looking forward to commercialization of LYMPRO Q4 '14 so we can start ramping up revenues to your Billion $ a year projections. Imagine what the stock price will be when you start applying multiples to sales. Can you say KAABOOOOMAGE?!!!!!
"AMBS MANF, Lympro equals dollars."
I agree with you 100% fouraces. "Hold for gold"
What we are actually seeing in this study is a 75% improvement in Ejection Fraction. Before treatment with intellicells EF was 20% and post treatment improved to 35%. Pretty amazing stuff!
saw over 30 million on the bid at .0049. 5.2 million on the bid at .005. high bid .0053. last .0053 starting to break.
news out!
news link
3.2 million on bid at .0081
.0053 x .0054 volume hasn't been too impressive this am but we're looking strong none the less. Over a million shares sitting on the bid at .0053. I think the most encouraging thing though is to see vndm get off the ask at .0054 with only a 10K block ask slap. VNDM now sitting at .0066 and VFIN at .10. I think we can run good today with a little buying pressure now that we aren't seeing unrelenting selling by MM's. Happy Valentine's day! Markets closed on monday. Enjoy the long weekend everyone.
It did hit a high of .009. How convenient to have sold in that .009 region!
LOL! The drop in price we just saw was from an amateur seller trying to get rid of his 1.3 million shares. We were hitting .0054 with some large blocks and then they put their 1.3 million for sale at .0052. Before that order could be filled it was lifted again and put at .0051. Only 400K shares went through at that price before they couldn't wait to lift it again and bid whack at .005. Funny! I'm sure if they just left their ask at .0053 they would have been filled by now. Unless of course the intention of that seller was to try and drop the price for whatever reason. Anyway, no big. Looks like we only have about a million shares on the ask all the way back up to .0054.
2 million ask slap just took out ask at .0053. Great job guys! I think this thing has wings. Now lets bust through vndm at .0054. I think a couple million should do the trick. Run for the hills!
what happened to those 7 million shares forming a wall at .0048? I see a million block go through slapping that ask followed by another 10K block and then all of a sudden it disappears. Seems to me that orders are being placed to create selling at lower prices. Also possible the hypothetical seller is on the receiving end buying on the bid. Nice strategy! Not going to work anymore since now we go higher. 2 million just got slapped at .005. I'm liking this sudden renewed interest. Look out for vndm at .0054. That a hole has been relentless with selling on the ask and only showing a 10K block. Anyway, bust through that and who knows where we'll end up. I think if MM's want to get more shares in their hands they'll have to take it much higher because volume down here at these levels is too low to make it worth their time. I'm assuming they've picked up as many shares as they can at these low levels and are looking to take it up at some point soon. .0049 X .0050 with only 447,000 shares left at .005.
7 million shares just sold and bought on the bid at .006. Must have been an all or none order that the MM's chose not to show on the bid or they just chose not to show the order at all. Took away bid support with that but you can see their intentions of not wanting to show 5 million on the bid, right? Makes it look weaker. Nice to see this strength after the last flush of stop limit orders taking us to .0047.
I think you are confusing the thread talking about board member Shish being on vaca in his home country India.
Thanks for the PM's Militia Man. I'm now your 268th follower. Best of luck to you in this game. I don't really care where the price goes day to day as i'm holding my shares for much higher prices. You can count on me not being shaken. Unfortunately, I'm out of cashish otherwise I'd be picking up some more but probably a good thing since I'm overweight in this position as is. Nice to see Vfin finally taken out of the ask with some nice buys. Wait a minute, spoke too soon a-hole just showed back up at .0056 with his 10.000 block.
.0056 finally getting hit and then vfin shows up on the ask at .0053. I can't stand that bastardo!
Possible, but not likely when the volume we are having today is so anemic. Could see some news released during market hours that could light a fire under this which could lead to that possibility. Anyway, we don't need to be on the FTD list to see this thing go parabolic. I actually think that now that they have covered and the volume is so low down here that we should move higher. As the saying goes, "know what you own". Congrats to whoever is picking up those shares at .0052 and .0053 and sorry to those who are selling at those prices. You'll learn your lesson one of these days. Put me down for 24 million shares Truth. I want to see your count above 700 million. I have mine locked for much higher prices.
RegSHOlist
They did cover their NSS. No longer on the FTD list. Maybe now they'll stop their manipulative games since it seems they aren't getting many sellers at these prices. Only 6.1 million shares traded in the first hour plus for this stock is pretty pathetic. They'll have to take it much higher if they want to see some volume. Anyway, any kind of positive pr from the company at this point and we should get some major LEGS. RSI at 52.57 primed and ready to run.
Did anyone else notice that it looks like we are finally off the reg sho list for FTD's? It looks like the MM's were able to cover their naked short positions over this last week by manipulating the action to keep us down and shake out the weak hands. And the manipulation continues this AM. This has been happening every morning the last week. Watch level 2. Market opens, you get a small rush of shares and then a small block at the low of the day. In this case we only had about 325K shares go through at the prices of .0057 and .0058. Then we see a block of 4000 shares go through at approximately 6:30:18 for .0057 and then the market makers essentially hit the pause button waiting for the orders to stack so they can process them in such a way to continue to drive the price down. 6 1/2 minutes later we finally get a 50K block going through at .0056. Then we don't see any trades until another 4 minutes later where they finally got some desperate seller to put a small block for sale at .0056. Now we're trading at .0055. It's too hard for me to believe that a stock with this much interest only trades 325K shares right at the open only to have no trade go through for 6 1/2 minutes and again another 4 minutes till we see a trade again. Only 410K shares 11 minutes after market opens. No way! I think this reasoning explains why we have been seeing millions of shares traded as T-trades after hours every single trading day lately. MM's balancing the books after a hard day of manipulation. Look at level 2. We are thin all the way to .0063 and even then I'm only see a block for 1 million shares. Peanuts. Hopefully after covering their NSS they are in accumulation mode during this consolidation phase before the next run higher. This is how MM's make money going up and going down.